PSA Burden and Age Shaped PSMA-PET Positivity After Prostatectomy
Biochemical recurrence after radical prostatectomy leaves clinicians balancing two overlapping questions: where is the disease now, and how far has it already traveled beyond the pelvis? In this retrospective single-institution cohort, PSMA-PET/CT detected locoregional recurrence in 77 of 140 men, a 55% positivity rate before salvage radiotherapy. The scan did more than mark visible disease; it separated patients into biologically distinct recurrence patterns that tracked with prior pathologic features and subsequent biochemical control.
Two variables stood out on multivariable analysis. Higher PSA at recurrence and older age independently predicted a positive PSMA-PET result, with PSA at recurrence showing an odds ratio of 2.07 and age an odds ratio of 1.07. The receiver operating characteristic analysis produced an AUC of 0.74, and the optimal threshold for scan positivity was 0.58 ng/mL. In practical terms, a rising PSA does not simply announce recurrence — it appears to raise the odds that the disease has crossed the imaging threshold of detectability. Age likely reflects a mixture of tumor biology, time since surgery, and the accumulated opportunity for microscopic disease to declare itself on molecular imaging.
A single PSA value did not behave like a neutral marker. It was the main signal that separated detectable from occult recurrence.
Prostate Bed Recurrence Traveled Differently From Pelvic Nodal Disease
Among PSMA-positive patients, the anatomic pattern of relapse carried its own clinical meaning. Disease confined to the prostate bed only was associated with a longer time to biochemical recurrence than recurrence involving pelvic lymph nodes, with median tBCR of 37.5 months versus 15 months. That gap suggests a slower, more locally contained disease course when recurrence remained centered in the surgical bed, compared with the more mobile biology implied by pelvic nodal involvement.
This is where molecular imaging begins to do real work beyond detection. A prostate-bed-only pattern can reflect residual microscopic disease near the original surgical field, a scenario that often remains more amenable to local salvage strategies. Pelvic nodal spread, by contrast, implies access to lymphatic drainage routes and a greater chance that the cancer has already diversified its anatomic foothold. In the context of salvage radiotherapy, those two patterns do not just describe location; they describe tempo.
Seminal vesicle invasion and pT-stage predicted pelvic nodal involvement on univariable analysis. Those features are familiar markers of locally advanced prostate cancer, and their association with nodal disease fits the biological logic of extension beyond the gland. Once tumor cells breach periprostatic barriers and involve structures linked to deeper local spread, the probability of lymphatic dissemination rises. The imaging findings therefore align with the surgical pathology, not replace it.
Pathologic Risk Features Mapped to Biochemical Control
Follow-up data were available for 124 of 140 patients, with a median follow-up of 31 months. Estimated biochemical disease-free survival after salvage treatment was 89.7% at 24 months, 80.2% at 36 months, and 54.1% at 60 months. The decline over time is clinically familiar: early control after salvage therapy can look reassuring, while later biochemical escape reveals the limits of local treatment when microscopic systemic or nodal disease persists.
On univariable Cox regression, several adverse pathologic features tracked with a higher risk of biochemical failure. Seminal vesicle invasion carried a hazard ratio of 2.39, extraprostatic extension carried a hazard ratio of 2.82, pT-stage carried a hazard ratio of 1.64, and pN-stage carried a hazard ratio of 1.83. None of these variables retained independent significance in multivariable analysis. The pattern is still informative. It suggests these pathologic factors cluster together, and once considered in combination, no single feature fully dominates the failure signal.
The signal is cumulative rather than singular.
For radiation oncologists, that matters because salvage radiotherapy decisions rarely hinge on one number alone. Pathology, PSA kinetics, imaging phenotype, and nodal status all shape treatment intensity and target selection. This cohort reinforces that adverse surgical pathology often travels with inferior biochemical outcomes, even when the final multivariable model does not isolate one feature as decisive. In other words, the tumor biology is being expressed through a bundle of related findings rather than a single dominant predictor.
What the Imaging Result Means for Salvage Treatment Planning
The study’s central message is straightforward: PSMA-PET is not merely a detection tool, but a biologic sorting instrument. PSA at recurrence and age helped identify which patients were most likely to have visible disease before salvage radiotherapy. Once detected, the location of recurrence separated slower prostate-bed-limited relapse from the more aggressive nodal pattern. That distinction can influence how clinicians think about field design, dose escalation, and the value of adding systemic therapy in patients with higher-risk anatomy.
The report also places limits around certainty. This was a retrospective, single-center study, which narrows generalizability and leaves room for treatment-selection bias. Patients received salvage radiotherapy with or without androgen deprivation therapy, but the abstract does not provide enough detail to dissect how that therapeutic variation affected outcomes. Median follow-up of 31 months is useful for early biochemical trends, yet still short relative to the long natural history of recurrent prostate cancer.
Even so, the data support a practical hierarchy: PSA burden and age helped predict whether PSMA-PET would reveal disease, while pathologic risk features and nodal spread tracked with worse biochemical control. For men with biochemical recurrence after prostatectomy, recurrence is not a binary event. It is a pattern, and the pattern already contains prognostic information before the first salvage radiation fraction is delivered.